SciELO - Scientific Electronic Library Online

vol.57 issue1The subjective visual vertical in vestibular diseasePopulation pharmacokinetics of carbamazepine in adults with epilepsy author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • Have no similar articlesSimilars in SciELO


Revista de investigación clínica

Print version ISSN 0034-8376


ROJAS, Rosalba et al. Applicability of the National Cholesterol Education Program III (NCEP-III) Guidelines for treatment of dyslipidemia in a non-Caucasian population: A Mexican Nation-Wide Survey. Rev. invest. clín. [online]. 2005, vol.57, n.1, pp.28-37. ISSN 0034-8376.

We assessed the impact of the NCEP-III recommendations in a population-based, nation-wide Mexican survey. Information was obtained from 15,607 subjects aged 20 to 69 years. In this report, only samples obtained after a 9 to 12 hours fast are included (2,201 cases). A cardiovascular risk equivalent was found in 10.5% and > 2 risk factors were present in 41.7% of the population. In 10% of cases, the LDL-C concentration was high enough to be an indication for a lipid-lowering drug (> 160 mg/dL), independent of the presence of risk factors. A quarter of the population was eligible for some form of treatment (lifestyle modifications in 15.9%, drug therapy in an additional 11.7%). Among cases with > 2 risk factors, a small percentage (1.8%) were identified as having a 10 year-risk > 20% and 86.3% were considered as having alO year-risk < 10%. The majority of the metabolic syndrome cases (84%) were identified as low-risk subjects. As a result, only 17.6% of them qualified for drug-based LDL-C lowering. Our data helps to estimate of the magnitude of the burden imposed on the Mexican health system, of lowering LDL-C for cardiovascular prevention. If we apply our results to the 2,000 Mexican population census more than 5.8 million cases nationwide may require LDL lowering drug therapy following the NCEP-III criteria.

Keywords : Cholesterol; Triglycerides; Mexico; Glucose intolerante; ATP-III.

        · abstract in Spanish     · text in English     · English ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License